Takeda Again Sues Par Over Generic Gout Drug

Law360, San Francisco (September 3, 2013, 3:05 PM EDT) -- Takeda Pharmaceuticals USA Inc. hit Par Pharmaceutical Cos. Inc. with a second patent suit Tuesday in Delaware federal court, claiming Par's revived effort to produce a generic gout medication infringes five of Takeda's patents.

The new complaint echoes one Par faced from Mutual Pharmaceutical Co. in April 2012, about the time Takeda acquired Mutual parent URL Pharma for $800M. After that lawsuit, Par voluntarily dropped its abbreviated new drug application with the U.S. Food and Drug Administration, but notified Takeda in July that it was renewing...
To view the full article, register now.